መነሻ › ፎሊኩላር ሊምፎማ › ካንሳስ
በካንሳስ ለፎሊኩላር ሊምፎማ የሚደረጉ ክሊኒካዊ ጥናቶች
ለፎሊኩላር ሊምፎማ የሚደረጉ 7 ጥናቶች በካንሳስ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በካንሳስ ውስጥ ያሉ ከተሞች
Official study text (English)
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- University of Kansas Cancer Center, Kansas City
- Lawrence Memorial Hospital, Lawrence
- University of Kansas Cancer Center-Overland Park, Overland Park
- እና 2 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT07215910A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Kansas Cancer Center, Kansas City
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07101328Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT06860594SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Kansas Medical Center, Kansas City
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦገስ 2026 · NCT05303519A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Local Institution - 0216, Westwood
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ሜይ 2026 · NCT06911502SynKIR-310 for Relapsed/Refractory B-NHL
- The University of Kansas Cancer Center, Fairway
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ኤፕሪ 2026 · NCT06544265A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- University of Kansas, Westwood
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ኖቬም 2025 · NCT05643742ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።